Johnson & Johnson announced yesterday,Executive Vice President and Chief Human Resources Officer Peter Fasolo Plans to Retire.After nearly 20 years at Johnson & Johnson, Peter Fasolo plans to retire by the end of this year. Additionally, Johnson & Johnson Medical (China) Ltd. recently announced internally,Kevin Chen (Chu-Hui Chen), General Manager of Johnson & Johnson Medical Technology China’s Cardiovascular and Professional Solutions Division, and Head of External Affairs and Market Access, has submitted his resignation to the company to pursue external development opportunities.

Johnson & Johnson Executive Vice President and Chief Human Resources Officer Peter Fasolo Plans to Retire.The company has selected Kristen Mulholland to succeed him, effective from October 1. Fasolo and Mulholland will collaborate during a transition period until Fasolo officially retires.

In 2004, Fasolo joined Johnson & Johnson as the Global Vice President of Human Resources for the Medical Technology sector. Before becoming the Chief Human Resources Officer and a member of the Executive Committee in 2010, he also served as the Chief Talent Officer.

His key focuses during his tenure included enhancing the company's diversity, equity, and inclusion efforts, as well as expanding employee benefits and policies. The company stated that he led initiatives to increase paid leave for military service, parenting, bereavement, volunteering, and mental health, among others.

Johnson & Johnson Chairman and CEO Joaquin Duato said, "Peter has led Johnson & Johnson's talent strategy over the past 16 years, demonstrating exceptional leadership during the global pandemic and the separation of our consumer health business." "Throughout his career, Peter has consistently placed two principles at the forefront of every decision and recommendation—our Credo values and a profound sense of responsibility toward our employees. He leaves behind strong leaders, a deep bench, and a culture of inclusiveness, care, and patient-centered focus."

Mulholland has accumulated extensive experience in Johnson & Johnson's innovative pharmaceuticals and medical technology fields. She also oversees the human resources department of Johnson & Johnson’s global operations. Mulholland has led corporate HR services, including performance and development as well as global total rewards.

Since joining Johnson & Johnson in 2005, Mulholland has held various HR leadership roles across different functions and businesses. She also played a key role in the spin-off of Kenvue's consumer business.

Joaquin Duato said, "I am delighted to appoint Mulholland to this important role, where she will apply her deep business acumen, talent expertise, and values-based approach to advance Johnson & Johnson's culture and operating model." "I am confident that her extensive experience and strong leadership will ensure Johnson & Johnson's human capital strategy delivers innovative, future-ready talent and culture to serve patients worldwide by advancing healthcare solutions."

Recently, Kevin Chen (ChuHui Chen), General Manager of Johnson & Johnson Medical Technology China’s Cardiovascular and Professional Solutions Division, as well as Head of External Affairs and Market Access, has submitted his resignation to the company and is seeking opportunities for external development.He worked at Johnson & Johnson until September 16, 2024. During the transition period, Edward Zhou will temporarily oversee the management of the Cardiovascular and Specialty Solutions division as well as the External Affairs and Market Access departments.

Chen Chuhui joined Johnson & Johnson in 2009, holding management positions in the Ethicon ASP division, Endo division’s ultrasonic scalpel business, Gynecare division, and Mentor division. After returning to Johnson & Johnson in 2015, he also took on important leadership roles such as head of channel management, strategic clients, operations, and professional education.

         
Johnson & Johnson stated that since Chen Chuhui became the General Manager of the Cardiovascular and Specialty Solutions (CSS) division, he has led the team to fulfill their steadfast commitment to patients and customers. The team continuously explores business growth opportunities and models, promotes digital innovation, and further strengthens and enhances the competitiveness and cohesion of the team. Currently, CSS China has become an important growth engine for the Asia-Pacific region and even globally.

In fact,Johnson & Johnson Medical Technology announced several personnel changes in the China region this year.

July,Johnson & Johnson announced that Edward Zhou (Zhou Mintao) will assume the position of President of Johnson & Johnson Medical Technologies China on July 25, 2024, while also becoming a member of the Johnson & Johnson Medical Technologies Asia-Pacific leadership team.Zhou Mintao had nearly three decades of work experience at Johnson & Johnson. He joined the company's consumer products business as a sales representative in 1992 and later became the General Manager of Johnson & Johnson's consumer products business in Singapore. After returning to China, he served as the General Manager of Johnson & Johnson’s Consumer Business in China. In 2015, he was appointed Vice President of the Ethicon division’s surgical business and became the General Manager of Ethicon in China in 2016.

April,Johnson & Johnson announces the departure of Song Weiqun, Chairman of Johnson & Johnson China and President of Johnson & Johnson Medical Technology China.In 2003, Song Weiqun joined Johnson & Johnson at its U.S. headquarters as the only global management trainee that year. Will Song's resume lists only one company to date: Johnson & Johnson. He is the first China-born Chairman of Johnson & Johnson's China region.

In April, Johnson & Johnson announced that Ronnie Chen (Chen Yanli) would serve as the Human Resources Leader for Johnson & Johnson Medical Technology China & OneHR China. Chen Yanli was previously the Vice President of Talent and Organizational Culture at Roche Pharmaceuticals China and the Head of the Market Access and Key Account Management Department for hospitals in China.

At the end of March, Johnson & Johnson Medical Technologies announced Tulio Oliveira as the new General Manager of its China Surgical Division. Prior to joining the China team, Tulio served as the Global Head of Johnson & Johnson Medical Technologies’ Advanced Stapling business. Tulio joined Johnson & Johnson in 2003 as an Ethicon sales representative for the Brazilian market. He subsequently worked in Brazil, the United States, Chile, and Argentina, with responsibilities spanning sales, marketing, new business development, global strategic marketing, strategic planning, and general management.

Johnson & Johnson was founded in 1886.It is one of the most comprehensive healthcare companies in the world with a wide range of business operations, covering three major fields: medical devices, pharmaceuticals, and consumer products.Headquartered in New Brunswick, New Jersey, USA, the company operates over 260 subsidiaries across 60 countries and regions worldwide. For more than a century, it has been committed to advancing healthcare, helping people stay healthy at every age and stage of life. Among them,Johnson & Johnson's medical device business covers four major fields: minimally invasive and open surgery, electrophysiology, orthopedics, and ophthalmology.Its diversified business pipeline has enabled Johnson & Johnson Medical to become the foreign medical device company with the highest revenue in China in recent years.

In September 2023, Johnson & Johnson announced a brand renewal.Integrate its two major businesses, medical technology and pharmaceuticals, under the name of Johnson & Johnson.Among them, the pharmaceutical business Janssen has been renamed Johnson & Johnson Innovative Medicine, while Johnson & Johnson MedTech remains unchanged.

This brand renewal,Highlight Johnson & Johnson's cross-business comprehensive strength in the healthcare field, continuously promoting healthcare innovation.Addressing the most severe health challenges and advancing the development of global health initiatives.

Johnson & Johnson Unveils New Brand Identity

It should be noted that, as one of the first multinational enterprises to enter the Chinese market since the reform and opening up, for many years,Johnson & Johnson has always been committed to providing high-quality innovative products to meet the growing healthcare needs.Bring health to Chinese patients and consumers, and build a Healthy China. Today,Johnson & Johnson's global businesses, including medical devices, pharmaceuticals, consumer goods, and Vision, have all entered China and have become leaders in their respective fields.

In recent years, due to the constantly changing global market environment, multinational device companies have been accelerating adjustments and transformations to enhance competitiveness. Among them, Johnson & Johnson has never stopped its innovative transformation through various methods such as spin-offs, reorganizations, and mergers and acquisitions. At the beginning of April, it announced the acquisition of Shockwave for a total transaction value of approximately $13.1 billion, strongly reinforcing its layout in cardiovascular interventions.

In response to the healthcare reform in the Chinese market, Johnson & Johnson is continuously transitioning to new models. As one of the fastest-growing markets for digital technology globally, Johnson & Johnson is accelerating its digital transformation through strategic layouts and the launch of digital upgrades. Moreover, China is the only market outside the United States where Johnson & Johnson has established R&D centers or departments across all its businesses.

How will Johnson & Johnson's recent personnel changes drive its further development in China? Will it better meet the changes and demands of the local market? Medical Device News will continue to follow up.

END

 

More exciting content

Welcome to follow WeChat Video Channel

Instrument Family

Related Reading

Tap for more!

Giant of Respiratory Devices, "Dismantled"

One Province Issues 136 Class B Licenses: 68 Linear Accelerators

"Blue Giant" Returning to Healthcare, or Will It Withdraw from China?

Evaporated nearly 140 billion, has China's largest medical aesthetics company imploded?

$34 Billion: Medical Device Giant Enters This Field

Minimally Invasive Surgery "Unicorn" Terminates STAR Market IPO

The 6th Deal This Year: Orthopedic Leader Acquires Again

Varian Greater China, Leadership Change

Well-known Imaging Company Lays Off 1,400 Employees in China

World's First AI+ROBOT Orthopedic Surgery Robot ROPA® Approved for Marketing

BusinessBusiness cooperation email: qxzj@landianyiliao.com